OSUR OraSure Technologies Inc.

2023 First Quarter Earnings Conference Call Wednesday, May 10, 2023, 5:00 p.m. ET

2023 First Quarter Earnings Conference Call Wednesday, May 10, 2023, 5:00 p.m. ET

BETHLEHEM, Pa., May 03, 2023 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2023 first quarter financial results and certain business developments for 5:00 p.m. ET (2:00 p.m. PT) on Wednesday, May 10, 2023.

May 10, 2023 schedule:

4:05 p.m. ET – 2023 first quarter financial results press release will be distributed.

Prior to the call - To participate in the teleconference, go to the following link to register and the teleconference number and a pin number for the teleconference will be sent to you:

 

5:00 p.m. ET - Conference call and simultaneous webcast begins.

The conference call will also be available via webcast, and may be accessed on the investor relations page of OraSure’s website, . Please click on the webcast link and follow the prompts for registration and access, 10 minutes prior to the call.

If you are unable to participate, the webcast will be archived on OraSure’s website shortly after the call has ended and will be available for 14 days.

Investor Contact:Media Contact:
Scott Gleason Amy Koch
SVP Investor Relations & Corp. Communications Director Corporate Communications
484-425-0588484-523-1815
 


EN
03/05/2023

Underlying

OSUROraSure Technologies Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OraSure Technologies Inc.

 PRESS RELEASE
Free
OSUR OraSure Technol...

OraSure to Launch OraQuick™ HIV Self-Test in Canada

OraSure to Launch OraQuick™ HIV Self-Test in Canada BETHLEHEM, Pa., Feb. 10, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OraSure”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its OraQuick™ HIV Self-Test has received a license from Health Canada for use in Canada. The OraQuick™ HIV Self-Test is a point-of-care rapid antibody test. It is Canada’s first oral HIV self-test and detects antibodies for both HIV-1 and HIV-2, enabling individuals to find out their HIV status with a simple oral swab in as little as ...

February 10, 2026 1 EN
 PRESS RELEASE
Free
OSUR OraSure Technol...

OraSure to Announce Fourth Quarter 2025 Financial Results and Host Ear...

OraSure to Announce Fourth Quarter 2025 Financial Results and Host Earnings Call on February 25th BETHLEHEM, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering fourth quarter 2025 financial results and certain business developments for 5 p.m. ET on February 25, 2026. A webcast of the conference call will be available on the investor relations page of OraSure’s website at . Please click on the webcast link and follow the prompts for registration and access at least 10 minutes prior to the call. The w...

February 9, 2026 1 EN
 PRESS RELEASE
Free
OSUR OraSure Technol...

OraSure Technologies Confirms Receipt of Director Nominations from Alt...

OraSure Technologies Confirms Receipt of Director Nominations from Altai Capital No Shareholder Action Required at This Time BETHLEHEM, Pa., Jan. 15, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OraSure” and “OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today confirmed that Altai Capital (“Altai”) has nominated two candidates, including the fund’s founder Rishi Bajaj, to stand for election to the Company’s Board of Directors (the “Board”) at its 2026 Annual Meeting of Stockholders. As previously announced, OraSure’s...

January 15, 2026 1 EN
 PRESS RELEASE
Free
OSUR OraSure Technol...

OraSure Submits CT/NG Molecular Self-Test and Colli-Pee™ Urine Collect...

OraSure Submits CT/NG Molecular Self-Test and Colli-Pee™ Urine Collection Device for FDA Review BETHLEHEM, Pa., Jan. 05, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) (“OraSure” and “OTI”), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that it submitted two separate applications at the end of 2025 to the U.S. Food and Drug Administration (FDA) for clearance of its rapid molecular self-test for Chlamydia trachomatis and Neisseria gonorrhoeae (CT/NG) as well as its Colli-Pee™ at-home urine collection device for sexu...

January 5, 2026 1 EN
 PRESS RELEASE
Free
OSUR OraSure Technol...

OraSure Technologies Issues Statement Regarding Altai Capital’s Intent...

OraSure Technologies Issues Statement Regarding Altai Capital’s Intent to Nominate Director Candidates No Shareholder Action Required at This Time BETHLEHEM, Pa., Dec. 17, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OraSure” and “OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today confirmed that Altai Capital (“Altai”) has notified the Company of its intent to nominate two candidates, including the fund’s founder, Rishi Bajaj, to stand for election to the Company’s Board of Directors (the “Board”) at its 2026 Annual ...

December 17, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch